differentiating among incretin agents for type 2 diabetes: weighing the evidence
DESCRIPTION
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence. Program Goals. Insulin Deficiency and Glucagon Hypersecretion in T2D. Postprandial Glucagon Is Excessive and Not Corrected by Exogenous Insulin. Incretin Hormome Physiology. Signal Transduction and GLP-1. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/1.jpg)
![Page 2: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/2.jpg)
![Page 3: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/3.jpg)
![Page 4: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/4.jpg)
![Page 5: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/5.jpg)
![Page 6: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/6.jpg)
![Page 7: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/7.jpg)
![Page 8: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/8.jpg)
![Page 9: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/9.jpg)
![Page 10: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/10.jpg)
![Page 11: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/11.jpg)
![Page 12: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/12.jpg)
![Page 13: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/13.jpg)
![Page 14: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/14.jpg)
![Page 15: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/15.jpg)
![Page 16: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/16.jpg)
![Page 17: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/17.jpg)
![Page 18: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/18.jpg)
![Page 19: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/19.jpg)
![Page 20: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/20.jpg)
![Page 21: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/21.jpg)
![Page 22: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/22.jpg)
![Page 23: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/23.jpg)
![Page 24: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/24.jpg)
![Page 25: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/25.jpg)
![Page 26: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/26.jpg)
![Page 27: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/27.jpg)
![Page 28: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/28.jpg)
![Page 29: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/29.jpg)
![Page 30: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/30.jpg)
![Page 31: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/31.jpg)
![Page 32: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/32.jpg)
![Page 33: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/33.jpg)
![Page 34: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/34.jpg)
![Page 35: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/35.jpg)
![Page 36: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/36.jpg)
![Page 37: Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence](https://reader030.vdocument.in/reader030/viewer/2022032708/56812dd5550346895d9321c4/html5/thumbnails/37.jpg)